Personalis, Inc. Research and Development Expense
Personalis, Inc. (PSNL) reported Research and Development Expense of $16.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- Personalis, Inc. research and development expense for the quarter ending 2026-06-30 was $16.34M, a 31.94% increase year-over-year.
- Personalis, Inc. research and development expense for the quarter ending 2026-03-31 was $14.54M, a 15.02% increase year-over-year.
- Personalis, Inc. research and development expense for the quarter ending 2025-12-31 was $13.07M, a 13.73% increase year-over-year.
- Personalis, Inc. research and development expense for the quarter ending 2025-09-30 was $12.17M, a 4.18% increase year-over-year.
- Personalis, Inc. research and development expense for fiscal 2025 was $50.26M, a 2.78% increase from fiscal 2024.
- Personalis, Inc. research and development expense for fiscal 2024 was $48.91M, a 24.50% decline from fiscal 2023.
- Personalis, Inc. research and development expense for fiscal 2023 was $64.78M, a 0.21% decline from fiscal 2022.
- Personalis, Inc. research and development expense for fiscal 2022 was $64.91M, a 31.64% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.34M 10-Q · filed 2026-08-04 | $30.88M 10-Q · filed 2026-08-04 | $43.95M derived: sum of 3 quarters · filed 2026-08-04 | $56.12M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $14.54M 10-Q · filed 2026-05-07 | $27.61M derived: sum of 2 quarters · filed 2026-05-07 | $39.78M derived: sum of 3 quarters · filed 2026-05-07 | $52.16M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $13.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $25.24M derived: sum of 2 quarters · filed 2026-02-26 | $37.62M derived: sum of 3 quarters · filed 2026-08-04 | $50.26M 10-K · filed 2026-02-26 |
| 2025-09-30 | $12.17M 10-Q · filed 2025-11-04 | $24.55M derived: sum of 2 quarters · filed 2026-08-04 | $37.19M 10-Q · filed 2025-11-04 | $48.69M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $12.38M 10-Q · filed 2026-08-04 | $25.02M 10-Q · filed 2026-08-04 | $36.52M derived: sum of 3 quarters · filed 2026-08-04 | $48.20M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $12.64M 10-Q · filed 2026-05-07 | $24.13M derived: sum of 2 quarters · filed 2026-05-07 | $35.82M derived: sum of 3 quarters · filed 2026-05-07 | $48.77M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $11.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $23.18M derived: sum of 2 quarters · filed 2026-02-26 | $36.13M derived: sum of 3 quarters · filed 2026-02-26 | $48.91M 10-K · filed 2026-02-26 |
| 2024-09-30 | $11.68M 10-Q · filed 2025-11-04 | $24.64M derived: sum of 2 quarters · filed 2025-11-04 | $37.41M 10-Q · filed 2025-11-04 | $51.02M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $12.96M 10-Q · filed 2025-08-05 | $25.73M 10-Q · filed 2025-08-05 | $39.34M derived: sum of 3 quarters · filed 2025-08-05 | $56.08M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $12.77M 10-Q · filed 2025-05-06 | $26.38M derived: sum of 2 quarters · filed 2025-05-06 | $43.12M derived: sum of 3 quarters · filed 2025-05-06 | $60.97M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $13.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $30.35M derived: sum of 2 quarters · filed 2025-02-27 | $48.20M derived: sum of 3 quarters · filed 2025-02-27 | $64.78M 10-K · filed 2025-02-27 |
| 2023-09-30 | $16.74M 10-Q · filed 2024-11-06 | $34.59M derived: sum of 2 quarters · filed 2024-11-06 | $51.16M 10-Q · filed 2024-11-06 | $67.73M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $17.85M 10-Q · filed 2024-08-07 | $34.42M 10-Q · filed 2024-08-07 | $50.99M derived: sum of 3 quarters · filed 2024-08-07 | $65.95M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $16.57M 10-Q · filed 2024-05-08 | $33.14M derived: sum of 2 quarters · filed 2024-05-08 | $48.10M derived: sum of 3 quarters · filed 2024-05-08 | $64.39M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $16.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $31.53M derived: sum of 2 quarters · filed 2024-02-28 | $47.81M derived: sum of 3 quarters · filed 2024-02-28 | $64.91M 10-K · filed 2024-02-28 |
| 2022-09-30 | $14.96M 10-Q · filed 2023-11-07 | $31.25M derived: sum of 2 quarters · filed 2023-11-07 | $48.34M 10-Q · filed 2023-11-07 | $62.85M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $16.29M 10-Q · filed 2023-08-08 | $33.39M 10-Q · filed 2023-08-08 | $47.90M derived: sum of 3 quarters · filed 2024-02-28 | $61.52M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $17.10M 10-Q · filed 2023-05-03 | $31.61M derived: sum of 2 quarters · filed 2024-02-28 | $45.23M derived: sum of 3 quarters · filed 2024-02-28 | $56.91M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $14.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $28.13M derived: sum of 2 quarters · filed 2024-02-28 | $39.82M derived: sum of 3 quarters · filed 2024-02-28 | $49.31M 10-K · filed 2024-02-28 |
| 2021-09-30 | $13.62M 10-Q · filed 2022-11-02 | $25.30M derived: sum of 2 quarters · filed 2022-11-02 | $34.80M 10-Q · filed 2022-11-02 | $43.32M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $11.69M 10-Q · filed 2022-08-03 | $21.18M 10-Q · filed 2022-08-03 | $29.70M derived: sum of 3 quarters · filed 2023-02-23 | $36.90M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $9.50M 10-Q · filed 2022-05-04 | $18.02M derived: sum of 2 quarters · filed 2023-02-23 | $25.21M derived: sum of 3 quarters · filed 2023-02-23 | $31.67M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $8.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $15.71M derived: sum of 2 quarters · filed 2023-02-23 | $22.18M derived: sum of 3 quarters · filed 2023-02-23 | $28.57M 10-K · filed 2023-02-23 |
| 2020-09-30 | $7.19M 10-Q · filed 2021-11-04 | $13.66M derived: sum of 2 quarters · filed 2021-11-04 | $20.05M 10-Q · filed 2021-11-04 | $27.42M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $6.46M 10-Q · filed 2021-08-04 | $12.86M 10-Q · filed 2021-08-04 | $20.23M derived: sum of 3 quarters · filed 2022-02-24 | $25.53M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $6.39M 10-Q · filed 2021-05-05 | $13.76M derived: sum of 2 quarters · filed 2022-02-24 | $19.07M derived: sum of 3 quarters · filed 2022-02-24 | $23.56M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $7.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $12.68M derived: sum of 2 quarters · filed 2022-02-24 | $17.17M derived: sum of 3 quarters · filed 2022-02-24 | $22.42M 10-K · filed 2022-02-24 |
| 2019-09-30 | $5.30M 10-Q · filed 2020-11-05 | $9.80M derived: sum of 2 quarters · filed 2020-11-05 | $15.04M 10-Q · filed 2020-11-05 | $19.33M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $4.50M 10-Q · filed 2020-08-06 | $9.74M 10-Q · filed 2020-08-06 | $14.02M derived: sum of 3 quarters · filed 2021-02-25 | $17.60M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $5.25M 10-Q · filed 2020-05-07 | $9.53M derived: sum of 2 quarters · filed 2021-02-25 | $13.10M derived: sum of 3 quarters · filed 2021-02-25 | $16.60M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $4.28M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $7.86M derived: sum of 2 quarters · filed 2021-02-25 | $11.36M derived: sum of 3 quarters · filed 2021-02-25 | $14.30M 10-K · filed 2021-02-25 |
| 2018-09-30 | $3.57M 10-Q · filed 2019-11-13 | $7.07M derived: sum of 2 quarters · filed 2019-11-13 | $10.02M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $3.50M 10-Q · filed 2019-08-13 | $6.45M 10-Q · filed 2019-08-13 | ||
| 2017-12-31 | $9.92M 10-K · filed 2020-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |